The termination of the ATM program is a signal of financial discipline or reduced near-term capital needs, but investors should watch for final Q1 2026 financials and pipeline updates as the next catalyst. The strong cash position supports operations into 2028 as previously guided.
Price Chart
Executive Summary
Spyre Therapeutics reported preliminary cash of $741M as of March 31, 2026, including $30M from legacy asset sales, while terminating its ATM offering. The cash update is positive, but halting equity financing suggests caution despite strong liquidity.
Key Financial Metrics
Key Facts
- Company expects ~$741M in cash, cash equivalents, and marketable securities as of March 31, 2026
- Cash includes $30M from legacy asset disposition, $23M of which is expected to be paid to CVR holders in Q2 2026
- Terminated at-the-market (ATM) prospectus, halting common stock sales under the existing agreement
- Sales Agreement with TD Securities remains in effect; new prospectus would be needed to restart sales
- No financial results finalized; this filing provides only preliminary cash guidance
Financial Impact
$741M cash position as of March 31, 2026, up from $486.2M reported on September 30, 2025
Risk Factors
- Preliminary figures are subject to change upon audit and final closing procedures
- Termination of ATM may signal reduced confidence in near-term equity markets or strategic shift in capital raising
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-024906 |
| Document: 0001628280-26-024906-index-headers.html | 0001628280-26-024906 |
| Document: 0001628280-26-024906-index.html | 0001628280-26-024906 |
| Document: 0001628280-26-024906.txt | 0001628280-26-024906 |
| 8-K Data (Synthetic) | 0001628280-26-024906 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access